Proteomics Industry Overview
Global Proteomics Market was valued at $17,988 million in 2015, and is expected to reach $44,452 million by 2022, supported by a CAGR of 13.7%. Proteomics is the study of the structure and functions of proteins that can be used in the drug discovery, diagnosis, and treatment of diseases. A proteome is never constant as it differs from one cell to other with time.
Proteomics is used to evaluate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. In addition, it finds extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis, which has led to the stellar growth of the proteomics market in the past few years. With the increase in awareness regarding the benefits of personalized medicines, companies and government organizations have increased their R&D expenditure on the development of proteomics. As per the proteomics market research report, it is estimated that reagents segment will continue to lead the overall market during the forecast period.
Global Proteomics Market Segmentation
Increasing popularity of personalized medicine is driving the demand for proteomic technologies
Personalized medicine is a new and better approach to healthcare based on each person's unique genetic makeup. In personalized medicine, diagnostic testing is often employed to select appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular & cellular analysis. Personalized medicine finds extensive applications in the diagnosis and treatment of cancer. Proteomics is an emerging field that can make unique contributions to the field of personalized medicines. It has the advantage over genomics-based assays as it offers direct examination of the molecular machinery of cell physiology, including protein expression, sequence variations & isoforms, posttranslational modification, and protein‐protein complexes. Advances in proteomic technologies have made important contribution to the development of personalized medicine by facilitating detection of protein biomarkers, proteomics-based molecular diagnostics, as well as protein biochips & pharmacoproteomics. For instance, NantHealth, Inc. launched Genomic Proteomic Spectrometry Cancer, or GPS Cancer, which is a comprehensive molecular test that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. As proteomics have important contribution in the field of personalized medicine, the impact of the driver is expected to increase during the study period with the increase in popularity of the use of personalized medicines in the treatment of cancer and neurodegenerative diseases.
Top Impacting Factors
Increasing R&D expenditure to drive the proteomics market size
Large number of organizations invest in the R&D of proteomics to understand the metabolic pathway involved in the progression of disease and the development of novel molecules for its treatment and diagnosis. In addition, organizations such as National Institutes of Health (NIH) and National Science Foundation (NSF) raise funds for various proteomics projects. For instance, in September 2016, NIH announced to fund research on “Proteomics, Immunoassay for TB Activation in HIV Patients”. In 2015, National Cancer Institute offered grants for Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. The governments of European countries also take various initiatives to promote proteomics research. The European Union’s Seventh Framework Programme supports proteomics research by funding a group of proteomics researchers from European institutes for the next four years. In Australia, with assistance from government funding, the R&D expenditure on proteomics is expected to increase by 58% in 2016.
Technological advancements to drive the proteomics market
The recent technological advancements in the field of proteomics is expected to spur the proteomics market. These advancements attract the interest of pharmaceutical & biotechnology companies to venture in the field of proteomics as the convenience of use of the instrument and the outcome of the procedure have improved. For instance, technological advancements such as increased resolution of mass spectrometry helps to extract more information from minimal amount of sample. Similarly, dual mass analyzers such as LC/MS, GC/MS, FT-MS, and MALDI-TOF/TOF help to provide more detailed information about protein structure. Moreover, the development of improved liquid chromatography and gel electrophoresis have significantly helped in the protein identification and separation methods. Two-dimensional gel electrophoresis, which is based on isoelectric focusing (IEF) and denaturing polyacrylamide gel matrix for protein separation, have also been developed by scientist recently. These technological advancements are expected to propel the proteomics market.
Proteomics help to bridge the gap between the understanding of genome expression and cellular behavior
Proteomics enables the study of proteomes (the entire complement of proteins that is or can be expressed by a cell, tissue, or organism) as well as their interactions. Moreover, it characterizes protein expression profiles and identifies protein structures, localizations, activities, modifications, and interactions in physiological or pathological states. As proteins perform most biological functions, proteomics bridges the gap between the information coded in the genome sequence and cellular behavior. For instance, hepatocellular carcinoma is the third leading cause of death globalwide. Chemotherapeutic treatment is ineffective against hepatocellular carcinoma (HCC); hence, surgical removal or liver transplantation is the only treatment possible. Proteomics studies of HCC may decode the mechanisms of HCC initiation and progression, and it also has the potential to discover novel diagnostic biomarkers and therapeutic targets.
High cost of instruments
High costs of the instruments utilized in proteomics restrain the growth of the market. The cost of mass spectrometers used in the study of proteomics is approximately $20,000. The price for ion exchange chromatography with fractions collection is around $250 per sample as per the proteomics and mass spectrometry services from Cornell University. Peptide quantitation by extracted ion chromatogram costs around $160 per sample. The high price of the instruments and reagents makes it difficult for developing countries to venture in the field of proteomics. In addition, the outcome of the study and trials are not always as per expectation and the results obtained may not be satisfactory. Hence, high costs restrict the growth of the proteomics industry.
Dearth of skilled researchers
The field of proteomics requires skilled researchers as scientists need to perform the critical, time-consuming task to interpret their proteomics data and extract meaningful biological information from the multiple, complex data sets. There is a shortage of skilled scientists as the field of proteomics is relatively new and there is lack of knowledge as to what proteomics can achieve, which restrain the growth of proteomics. However, many organizations arrange training workshops to educate researchers regarding proteomics. For instance, EMBO Workshop was organized in Varna, Italy from 31 July to 06 August 2016 to educate postdoctoral scientists from academics and industry with insights into proteomic technologies and applications in the life sciences.
Key players in proteomics industry include Thermo Fisher Scientific Corporation, Agilent Technologies, Luminex Corporation, Danaher Corporation, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Waters Corporation, Caprion Proteomics Inc., and PerkinElmer, Inc. Other players in the value chain include Quanterix Corporation, Courtagen Life Sciences, Inc., Sera Prognostics, Inc., Applied Proteomics, Inc., MRM Proteomics, Inc., Sonata Biosciences, Inc., Applied Biomics, Inc., Antigen Discovery, Inc., Bionexus, Inc., Correlia Biosystems, Inc., Digilab, Inc., GenScript Corporation, Creative Biogene and Proteome Sciences.
KEY MARKET BENEFITS OF PROTEOMICS MARKET:
The study provides an in-depth analysis of the global proteomics market with current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Proteomics market analysis by components helps understand the various types of instruments used.
Competitive intelligence highlights the business practices followed by leading players across various regions.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these geographies.
Key market players are profiled in the report and their strategies are analyzed thoroughly, which interpret the competitive outlook of the global proteomics industry.
Extensive analysis of the proteomics market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Proteomics Market Key Segments
Supercritical Fluid Chromatography
Surface Plasmon Resonance
Protein Fractionation Systems
Protein Fractionation Reagents
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA